Get the Stockscreener App
8.90
0.91%
0.08
After Hours:
8.91
0.010
+0.11%
Candel Therapeutics Inc Stock (CADL) Latest News
Candel therapeutics CTO sells $275,947 worth of common stock - Investing.com
Candel therapeutics CFO Charles Schoch sells $44,169 in stock - Investing.com India
Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors UK
Candel Therapeutics appoints cancer immunology expert to research advisory board - Proactive Investors USA
Candel Therapeutics Appoints Renowned Pancreatic Cancer - GlobeNewswire
Top Pancreatic Cancer Expert Joins Candel Therapeutics Following Promising Trial Results - StockTitan
H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com India
When (CADL) Moves Investors should Listen - Stock Traders Daily
Candel Therapeutics Reports Positive Clinical Trial Results - TipRanks
Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline - Proactive Investors USA
Candel Therapeutics, Inc. SEC 10-K Report - TradingView
Candel Therapeutics Reports Positive Data from Multiple Clinical Trials and Outlines Plans for CAN-2409 and CAN-3110 - Nasdaq
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Candel's Breakthrough: Phase 3 Trial Shows 30% Cancer Risk Reduction, Extends Survival 2.5x - StockTitan
Small cap wrap: Fineqia, Ocean Power Technologies, NEXE Innovations... - Proactive Investors UK
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Acquired by Rhumbline Advisers - Defense World
Oppenheimer & Co. Inc. Purchases Shares of 37,915 Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
(CADL) Technical Data - Stock Traders Daily
Genetic Technologies (NASDAQ:GENE) & Candel Therapeutics (NASDAQ:CADL) Head-To-Head Contrast - Defense World
HC Wainwright Has Negative Forecast for CADL FY2025 Earnings - Defense World
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week - MSN
Candel Therapeutics (NASDAQ:CADL) Earns Buy Rating from HC Wainwright - MarketBeat
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial resultsICYMI - Proactive Investors USA
Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance UK
Insiders Enjoy US$1.3m Return After Buying Candel Therapeutics Stock - Simply Wall St
Canaccord Genuity Group Issues Positive Forecast for Candel Therapeutics (NASDAQ:CADL) Stock Price - MarketBeat
Candel reports extended survival in Phase II CAN-2409 trial - The Pharma Letter
Promising Potential of Candel Therapeutics’ CAN-2409: Analyst Recommends ‘Buy’ Based on Compelling Phase 2 Trial Results and Future Outlook - TipRanks
Candel stock plunges 20% following Phase 2 data release - MSN
Candel Therapeutics reports Phase 2 trial shows extended survival in Pancreatic Cancer - Proactive Investors USA
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data - Seeking Alpha
Small cap headlines: Candel Therapeutics, Sintana Energy, Trust Stamp, Tiziana Life Sciences... - Proactive Investors UK
Candel Therapeutics stock drops despite OS improvement in PDAC trial - Yahoo Finance
Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data -February 25, 2025 at 01:36 pm EST - Marketscreener.com
Candel stock plunges 20% following Phase 2 data release (CADL:NASDAQ) - Seeking Alpha
Candel Therapeutics Announces Positive Long-Term Survival Data From CAN-2409 Phase 2 Trial - Nasdaq
Candel Therapeutics reports significant survival benefit for pancreatic cancer therapy - Proactive Investors USA
Candel Therapeutics stock rises on positive trial data By Investing.com - Investing.com Canada
Candel Therapeutics stock rises on positive trial data - Investing.com India
Candel Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Candel Therapeutics Reports Positive Final Survival Data for CAN-2409 in Borderline Resectable Pancreatic Cancer - Nasdaq
Candel Therapeutics Announces Positive Final Survival Data - GlobeNewswire
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 ... - Post Register
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer - StockTitan
Candel Therapeutics (NASDAQ:CADL) Coverage Initiated at Citigroup - MarketBeat
(CADL) Trading Report - Stock Traders Daily
Candel Therapeutics (NASDAQ:CADL) Coverage Initiated at Canaccord Genuity Group - MarketBeat
Vontobel Holding Ltd. Sells 3,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Citigroup Begins Coverage on Candel Therapeutics (NASDAQ:CADL) - Defense World
Candel Therapeutics Inc (CADL) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Citi sets $25 target on Candel Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice - NewsBreak
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Large Decline in Short Interest - MarketBeat
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):